



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 7/48, 38/48</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 95/07688</b> <b>(43) International Publication Date:</b> 23 March 1995 (23.03.95)
<b>(21) International Application Number:</b> PCT/EP94/03001 <b>(22) International Filing Date:</b> 8 September 1994 (08.09.94) <b>(30) Priority Data:</b> 9319103.9 15 September 1993 (15.09.93) GB 9405639.7 22 March 1994 (22.03.94) GB <b>(71) Applicant (for AU BB CA GB IE KE LK MN MW NZ SD TT only):</b> UNILEVER PLC [GB/GB]; Unilever House, Blackfriars, London EC4P 4BQ (GB). <b>(71) Applicant (for all designated States except AU BB CA GB IE KE LK MN MW NZ SD TT):</b> UNILEVER N.V. [NL/NL]; Weena 455, NL-3013 AL Rotterdam (NL). <b>(72) Inventors:</b> RAWLINGS, Anthony, Vincent; 509 Spencer Drive, Wyckoff, NJ 07481 (US). WATKINSON, Allan; 20 Hunts Path, Oakley, Bedford MK43 7SR (GB). <b>(74) Agent:</b> EVANS, Jacqueline, G., V.; Unilever plc, Patent Division, Colworth House, Sharnbrook, Bedford MK44 1LQ (GB).		<b>(81) Designated States:</b> AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD). <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> SKIN CARE METHOD AND COMPOSITION <b>(57) Abstract</b> <p>A composition for topical application to the skin for alleviation or prevention of dry flaky skin conditions, dandruff or acne comprising one or more stratum corneum trypsin-like enzymes. The composition may further comprise an additional enzyme selected from glycosidases, other proteases, lipases and mixtures thereof. Optional additional active ingredients include sunscreens, lipids, hydroxy carboxylic acids and ketocarboxylic acids.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

SKIN CARE METHOD AND COMPOSITION

5 The present invention relates to compositions for topical application to the skin and their cosmetic and pharmaceutical use. In particular, the invention relates to compositions comprising stratum corneum trypsin-like enzymes and their use in alleviating or preventing conditions involving abnormal desquamation by facilitating  
10 desmosomal degradation.

In normal, healthy epidermis the continuous production of new stratum corneum is balanced by a well-regulated shedding of corneocytes from the skin surface. Little is  
15 known about this desquamation process at the molecular level.

It has been shown by A. Lundström and T. Egelrud (J. Invest Dermatol, (1988) 91 340-343; Arch Dermatol Res (1990) 282  
20 234-237; J. Invest Dermatol (1990) 94 216-220) that cohesion between cells in the stratum corneum is dependant on protein structures. These structures must be degraded before cell dissociation can occur.

25 Furthermore, evidence has been provided to show that cell dissociation is preceded by a degradation of the extracellular parts of desmosomes (T. Egelrud (1992) European Journal of Dermatology 2 46-49).

30 It is thought that the process of desquamation involves proteolytic degradation of desmosomes, causing the cohesive links between the cells to break down and thereby allowing detachment of peripheral corneocytes from the surface of the stratum corneum.

35 Little is known about the proteases thought to be involved in the desquamatory process. One particular protease, the

- 2 -

serine protease stratum corneum chymotryptic-like enzyme (SCCE) has been implicated as a putative desmosomal degrading enzyme (see A. L ndstrom and T. Egelrud, Acta Derm Venereol (Stockh) (1991) 71, 471-474).

5

The present inventors have now found that the stratum corneum additionally contains serine proteases having trypsin-like substrate specificity, hereinafter referred to as stratum corneum trypsin-like enzymes (SCTE), which may be involved in the process of cell dissociation (desquamation) and desmosomal degradation. These enzymes are therefore of interest in the treatment of conditions where the underlying aetiology indicates that assisting the processes of desmosomal degradation and/or desquamation would be beneficial.

10

15

Accordingly the invention provides a composition for topical application to the skin, comprising one or more stratum corneum trypsin-like enzymes.

20

As used herein, the term "stratum corneum trypsin-like enzyme" means a stratum corneum serine protease, or a pro-enzyme thereof, which in its active form exhibits similar substrate sensitivity and inhibitor sensitivity to trypsin. More specifically, the term "stratum corneum trypsin-like enzyme" means a serine protease, or a pro-enzyme thereof, which in its active form is inhibited by antipain, and leupeptin. More particularly, the term "stratum corneum trypsin-like enzyme" means an enzyme which in its active form is capable of decomposing the substrate boc-phe-ser-arg-aminomethylcoumarin (AMC).

25

30

It will be appreciated that a pro-enzyme is an inactive form of the enzyme which may be activated by appropriate proteolytic cleavage to give the active form.

35

Suitable stratum corneum trypsin-like enzymes for use

- 3 -

according to the present invention have apparent molecular weights, as determined by the method of comparing the electrophoretic mobility with standard proteins on sodium dodecyl sulphate polyacrylamide gel electrophoresis of  
5 24kDa, 26kDa and 27kDa.

Preferably the composition comprises 0.00001 to 50% more preferably 0.001 to 20% and even more preferably 0.001 to 0.1% by weight of the composition stratum corneum protease  
10 enzyme.

Stratum corneum trypsin-like enzymes may be extracted from human or animal skin or callus by high salt solution (e.g. 1M NaCl), detergent or solvent extraction, and purified by  
15 chromatography or electrophoretic techniques. Recombinant stratum corneum trypsin-like enzymes may also be produced by biotechnological means by the over-expression of the gene in yeast, bacteria, plant or mammalian cells.

Compositions according to the invention may also include an additional enzyme selected from glycosidases, other proteases, lipases or similar lipid modifying enzymes, ceramidases and mixtures thereof. Preferably the composition comprises 0.00001 to 50%, more preferably 0.001  
20 to 20%, even more preferably 0.001 to 0.1% by weight of the composition of the additional enzyme.

Glycosidases, other proteases and lipases for inclusion in the compositions according to the invention may suitably be  
30 isolated from animal, plant, fungal or bacterial sources.

Typical glycosidases include neuraminidase, mannosidase, galactosidase, glucosidase, N-acetyl glucosaminidase and N-acetyl galactosaminidase. Preferably these may be isolated  
35 from plant sources including almonds, green coffee beans, and spinach, or may be obtained commercially.

- 4 -

Suitable additional proteases include bromelain, papain, chymotrypsin and chymotrypsin-like enzymes, stratum corneum chymotryptic-like enzyme, lysosomal cathepsin and cathepsin-like enzymes, alcalase, savinase, chymopapain, 5 clostripain, endoproteinase Asp N, protease V.8, proteinase K, subtilisin, thermolysin, plasmin, pronase, and trypsin and trypsin-like enzyme. Preferably the protease may be isolated from plant sources including the seeds of wheat, 10 barley, maize, oilseed rape, cocoa, linseed, illipe, shea nut, palm kernal, jojoba bean, pea, green bean, broad bean, soya bean and sunflower, and olives, papaya, pineapple, coconut, tomato and figs.

Lipases, or similar lipid modifying enzymes, may be 15 isolated from plant, animal or bacterial sources. Suitable enzymes include lipolase, pancreatic lipases, phospholipases, ceramidase, aryl sulphatase, cholesterol esterase, candida rugosa OF360 lipase, humicola sp. lipase, pseudomonas sp. lipase and Candida antarctica A and B 20 lipases.

Compositions according to the invention preferably also comprises a vehicle to act as a dilutant, dispersant or 25 carrier for the active ingredients in the composition, so as to facilitate their distribution when the composition is applied to the skin and/or hair. Preferably the vehicle is cosmetically and/or pharmaceutically acceptable.

Vehicles other than water can include liquid or solid 30 emollients, solvents, humectants, thickeners and powders typically found in cosmetic formulations. Examples of each of these types of vehicle, which can be used singly or as mixtures of one or more vehicles, are as follows:

35 Emollients, such as stearyl alcohol, glyceryl monoricinoleate, glyceryl monostearate, mink oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl

- 5 -

palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, eicosanyl alcohol, behenyl alcohol, cetyl palmitate, silicone oils such as dimethylpolysiloxane, di-  
5 n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, cocoa butter, corn oil, cotton seed oil, tallow, lard, olive oil, palm kernel oil, rapeseed oil, safflower seed oil, evening primrose oil,  
10 soybean oil, sunflower seed oil, avocado oil, olive oil, sesame seed oil, coconut oil, arachis oil, castor oil, acetylated lanolin alcohols, petroleum jelly, mineral oil, butyl myristate, isostearic acid, palmitic acid, isopropyl linoleate, lauryl lactate, myristyl lactate,  
15 decyl oleate, myristyl myristate;

Propellants, such as air, propane, butane, isobutane, dimethyl ether, carbon dioxide, nitrous oxide;

20 Solvents, such as squalene, squalane, ethyl alcohol, methylene chloride, isopropanol, acetone, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethyl sulphoxide, dimethyl formamide, tetrahydrofuran;

25 Humectants, such as polyhydric alcohols including glycerol, polyalkylene glycols and alkylene polyols and their derivatives, including propylene glycol, dipropylene glycol polypropylene glycol, polyethylene glycol and derivatives  
30 thereof, sorbitol, hydroxysorbitol, 1,3-butylene glycol, 1,2,6-hexanetriol, ethoxylated glycerol, propoxylated glycerol and mixtures thereof.

35 Powders, such as chalk, talc, fullers earth, kaolin, starch, gums, colloidal silica sodium polyacrylate, tetra alkyl and/or trialkyl aryl ammonium smectites, chemically modified magnesium aluminium silicate, organically modified

- 6 -

montmorillonite clay, hydrated aluminium silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol monostearate.

5 The vehicle will usually form from 10 to 99.9%, preferably from 50 to 99% by weight of the emulsion, and can, in the absence of other adjuncts, form the balance of the composition.

10 A particularly convenient form of the composition according to the invention is an emulsion, in which case an oil or oily material will normally be present, together with an emulsifier to provide either a water-in-oil emulsion or an  
15 oil-in-water emulsion, depending largely on the average hydrophilic-lyophilic balance (HLB) of the emulsifier employed.

Compositions according to the invention can optionally  
20 comprise one or more oils or other materials having the properties of an oil.

Examples of suitable oils include mineral oil and vegetable oils, and oil materials, such as those already proposed  
25 herein as emollients. Other oils or oily materials include silicone oils, both volatile and non-volatile, such as polydimethyl siloxanes.

The oil or oily material, when present for the purposes for  
30 forming an emulsion, will normally form up to 90%, preferably from 10 to 80% by volume of the composition.

Compositions according to the invention may also optionally  
35 comprise one or more emulsifiers the choice of which will normally determine whether a water-in-oil or an oil-in-water emulsion is formed.

When a water-in-oil emulsion is required, the chosen



- 7 -

emulsifier or emulsifiers should normally have an average HLB value of from 1 to 6. When an oil-in-water emulsion is required, a chosen emulsifier or emulsifiers should have an average HLB value of >6.

5

Examples of suitable emulsifiers are set out below in Table 1 in which the chemical name of the emulsifiers is given together with an example of a trade name as commercially available, and the average HLB value.

10

TABLE 1

15

20

25

30

35

Chemical Name of Emulsifier	Trade Name	HLB Value
Sorbitan trioleate	Arlacel 85	1.8
Sorbitan tristearate	Span 65	2.1
Glycerol monooleate	Aldo MD	2.7
Glycerol monostearate	Atmul 84S	2.8
Glycerol monolaurate	Aldo MC	3.3
Sorbitan sesquioleate	Arlacel 83	3.7
Sorbitan monooleate	Arlacel 80	4.3
Sorbitan monostearate	Arlacel 60	4.7
Poloxyethylene (2) stearyl ether	Brij 72	4.9
Poloxyethylene sorbitol beeswax derivative	G-1702	5
PEG 200 dilaurate	Emerest 2622	6.3
Sorbitan monopalmitate	Arlacel 40	6.7
Polyoxyethylene (3.5) nonyl phenol	Emulgen 903	7.8
PEG 200 monostearate	Tegester PEG 200 MS	8.5
Sorbitan monolaurate	Arlacel 200	8.6
PEG 400 dioleate	Tegester PEG 400-DO	8.8

- 8 -

	Polyoxyethylene (5)		
	monostearate	Ethofat 60-16	9.0
	Polyoxyethylene (4) sorbitan		
	monostearate	Tween 61	9.6
5	Polyoxyethylene (4) lauryl		
	ether	Brij 30	9.7
	Polyoxyethylene (5) sorbitan		
	monooleate	Tween 81	10.0
	PEG 300 monooleate	Neutronyx 834	10.4
10	Polyoxyethylene (20)		
	sorbitan tristearate	Tween 65	10.5
	Polyoxyethylene (20)		
	sorbitan trioleate	Tween 85	11.0
	Polyoxyethylene (8)		
15	monostearate	Myrj 45	11.1
	PEG 400 monooleate	Emerest 2646	11.7
	PEG 400 monostearate	Tegester PEG 400	11.9
	Polyoxyethylene 10		
	monooleate	Ethofat 0/20	12.2
20	Polyoxyethylene (10)		
	stearyl ether	Brij 76	
	12.4Polyoxyethylene (10)		
	cetyl ether	Brij 56	12.9
	Polyoxyethylene (9.3)		
25	octyl phenol	Triton X-100	13.0
	Polyoxyethylene (4)		
	sorbitan monolaurate	Tween 21	13.3
	PEG 600 monooleate	Emerest 2660	13.7
	PEG 1000 dilaurate	Kessco	13.9
30	Polyoxyethylene sorbitol		
	lanolin derivative	G-1441	14.0
	Polyoxyethylene (12)		
	lauryl ether	Ethosperse LA-12	14.4
	PEG 1500 dioleate	Pegosperse 1500	14.6
35	Polyoxyethylene (14)		
	laurate	Arosurf HFL-714	14.8

- 9 -

	Polyoxyethylene (20)		
	sorbitan monostearate	Tween	14.9
	Polyoxyethylene 20 sorbitan		
	monooleate	Tween 80	15.0
5	Polyoxyethylene (20)		
	stearyl ether	Brij 78	15.3
	Polyoxyethylene (20)		
	sorbitan monopalmitate	Tween 40	15.6
	Polyoxyethylene (20) cetyl		
10	ether	Brij 58	15.7
	Polyoxyethylene (25)		
	oxypropylene	G-2162	16.0
	monostearate		
	Polyoxyethylene (20)		
15	sorbitol monolaurate	Tween 20	16.7
	Polyoxyethylene (23)		
	lauryl ether	Brij 35	16.9
	Polyoxyethylene (50)		
	monostearate	Myrj 53	17.9
20	PEG 4000 monostearate	Pegospense 4000	
		MS	18.7

-----

25 The foregoing list of emulsifiers is not intended to be limiting and merely exemplifies selected emulsifiers which are suitable for use in accordance with the invention.

It is to be understood that two or more emulsifiers can be employed if desired.

30 The amount of emulsifier or mixtures thereof, to be incorporated in the composition of the invention, when appropriate is from 1 to 50%, preferably from 2 to 20% and most preferably from 2 to 10% by weight of the composition.

35 The compositions of the invention can also comprise water, usually up to 80%, preferably from 5 to 80% by volume.

- 10 -

Emulsifiers or surfactants in the form of silicone polymers may be incorporated into compositions of the present invention in place of or in addition to the optional emulsifier(s) already mentioned.

5

A particularly preferred silicone surfactant is cyclomethicone and dimethicone copolyol, such as DC 3225C Formulation Aid available from DOW CORNING. Another is laurylmethicone copolyol, such as DC Q2-5200, also available from Dow Corning.

10

The amount of silicone surfactant, when present in the composition will normally be up to 25%, preferably from 0.5 to 15% by weight of the emulsion.

15

Various other adjuncts conventionally found in cosmetic or pharmaceutical formulations may optionally be present in the compositions according to the present invention. The include preservatives, such as para-hydroxy benzoate esters; antioxidants, such butyl hydroxy toluene; humectants, such as glycerol, sorbitol, 2-pyrrolidone-5-carboxylate, dibutylphthalate, gelatin, polyethylene glycol, preferably PEG 200-600; buffers, such as lactic acid together with a base such as triethanolamine or sodium hydroxide; surfactants, such as glycerol ethers, waxes, such as beeswax, ozokerite wax, paraffin wax; plant extracts, such as Aloe vera, cornflower, witch hazel, elderflower, cucumber; thickeners; activity enhancers; colourants and perfumes.

20

25

30

Various types of active ingredients may optionally be present in the compositions according to the present invention. These include sunscreens, hydroxy carboxylic acids and ketocarboxylic acids or esters thereof and lipids such as ceramides, pseudoceramides (synthetic ceramide-like structures), polyol fatty acid polyesters, sterols, phospholipids, galactosyldiacylglycerols,


35

- 11 -

glycosphingolipids, fatty acids or esters thereof, and mixtures thereof.

Suitable sunscreens include those materials commonly used to block ultraviolet light and may include inorganic sunscreen materials, such as ultrafine titanium dioxide, or organic sunscreens such as p-aminobenzoic acid and esters thereof, ethylhexyl p-methoxycinnamate, 2-ethoxyethyl p-methoxycinnamate or butylmethoxydibenzoylmethane, and mixtures thereof. It will be appreciated that the amount of sunscreen employed will vary depending on the degree of protection required.

Suitable ceramides and synthetic analogues thereof which may be employed are disclosed in European patent application EP-A-587288 which is incorporated by reference herein. Preferred ceramides have the structure.



where A represents - CH<sub>2</sub> - ; - CHOR<sub>3</sub> - ; - CH=CH - or - CHOY -

R represents a linear or branched saturated or unsaturated, hydroxylated or non-hydroxylated aliphatic hydrocarbon group having from 1 to 49 carbon atoms or a subgroup (2).



R<sub>1</sub> represents a linear or branched, saturated or unsaturated, hydroxylated or non-hydroxylated aliphatic hydrocarbon group having from 8 to 28 carbon atoms;

R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> individually represent H, a phosphate residue

- 12 -

or a sulphate residue;

$R_4$  represents H, a phosphate residue, a sulphate residue or sugar residue;


5

a is an integer of from 1 to 49

b is an integer of from 10 to 98

m is 0 or 1

10 Y represents H or a residue of a  $C_{1-22}$  fatty acid having the general structure (3)



where Z is - OH or an epoxy oxygen

x is an integer of from 0 to 20

y is an integer of from 0 to 40


20 and z is 0 or an integer of from 1 to 4

Ceramides having the general structure (1) are naturally occurring and can be isolated from a suitable plant source or from animal tissue such as pig skin or neural tissue.  
25 Ceramides can also be synthesised.

Particular preferred examples of ceramides are ceramide-1, ceramide-2 and ceramide-3.

30 Pseudoceramides are preferably selected from pseudoceramides (i.e. synthetic ceramide like structures) having the general structure (4):

- 13 -



where B represents - OCH<sub>2</sub> - or CHOH.

R<sub>6</sub> represents a linear or branched, saturated or unsaturated, hydroxylated or non-hydroxylated aliphatic hydrocarbon group having from 1 to 49 carbon atoms or the subgroup (2).

R<sub>7</sub> represents a linear or branched, saturated or unsaturated, hydroxylated or non-hydroxylated hydrocarbon group having from 8 to 28 carbon atoms.

R<sub>8</sub> represents H, or a subgroup - (CH<sub>2</sub>)<sub>c</sub>COOH, where c is an integer of from 1 to 6, or a subgroup having the structure (5).



where X<sub>1</sub>, X<sub>2</sub> and X<sub>3</sub> each individually represent H, a C<sub>1-3</sub> alkyl or a C<sub>1-3</sub> hydroxyalkyl;

d is 0 or an integer of from 1 to 4

e is 0 or 1

n is 0 or 1

and p is 0 or 1;

R<sub>9</sub> represents H, a phosphate residue, a sulphate residue or a sugar residue.

- 14 -

5 Polyol fatty acid polyesters are fatty acid polyesters derived from any aliphatic or aromatic polyol which has at least 4 free hydroxyl groups, of which at least 60% of these free hydroxyl groups are then esterified with one or more fatty acids having from 8 to 22 carbon atoms. The polyol from which the polyol fatty acid polyesters are derived are preferably chosen from sugar polyols, which comprise mono-, di- and polysaccharides.

10 Particularly preferred polyol fatty acid polyesters are sucrose fatty acid polyesters where the ester is derived from lauric acid or natural oils, such as palm oil, palm kernal oil, soyabean oil, coconut oil, fish oil and mixtures thereof.

15 Preferably the amount of the lipid component where present in the composition according to the invention is from 0.00001 to 50%, more preferably from 0.001 to 20% and most preferably from 0.1 to 10% by weight of the composition.

20 Compositions according to the invention may also suitably comprise hydroxy carboxylic acids and keto carboxylic acids, esters thereof and mixtures thereof.

25 The hydroxy acid can be chosen from  $\alpha$ -hydroxy acids,  $\beta$ -hydroxyacids, other hydroxycarboxylic acids and mixtures thereof.

30 Preferably the hydroxy acid (ii) is chosen from  $\alpha$ -hydroxy acids having the general structure:



35 wherein  $R_1$  and  $R_2$  are H, alkyl, aralkyl or aryl group of saturated or unsaturated, isomeric or non-isomeric, straight or branched chain or cyclic form, having 1 to 30 carbon atoms, and in addition  $R_2$  may carry F, Cl, Br, I, N,



- 15 -

S, OH, CHO, COOH and alkoxy group having 1 to 9 carbon atoms; and mixtures thereof.

5 The alpha hydroxy acids may be present as a free acid or an ester form, or in a salt form with an organic base or an inorganic alkali. The typical alkyl, aralkyl and aryl groups for R<sub>1</sub> and R<sub>2</sub> include methyl, ethyl, propyl, isopropyl, butyl, pentyl, octyl, lauryl, stearyl, benzyl and phenyl, etc.

10

D, DL, or L stereoisomeric forms of an alpha hydroxy acid may be employed compositions. The L form is preferred.

15

Suitable alpha hydroxy acids which may be used include, but are not limited to, alpha hydroxy acetic acid (also known as "glycolic acid"), alpha hydroxypropionic acid (also known as "lactic acid"), alpha hydroxyoctanoic acid (also known as "alpha hydroxy caprylic acid"), alpha hydroxydodecanoic acid (also known as "alpha hydroxy lauric acid") and mixtures thereof.

20

Suitable esters include, but are not limited to, alkyl esters (for example, methyl, ethyl, propyl, pentyl, hexyl, octyl esters) and mono-, di- or triglycerides, or mixtures thereof.

25

Suitable salts of alpha hydroxy acids include but are not limited to sodium, potassium, ammonium, triethanolamine, calcium, lithium salts. The salts may be obtained commercially or they may be prepared by methods known in the art, e.g., neutralizing an alpha hydroxy acid with a suitable base, such as hydroxide bases of ammonium, potassium, sodium.

30

35 Conveniently, a mixture of alpha hydroxy acids may be employed. A suitable mixture comprises lactic acid, alpha hydroxy octanoic acid and alpha hydroxy lauric acid.

- 16 -

The preferred compositions according to the invention contain at least 60% of an alpha hydroxy acid in L-configuration, by weight of total alpha hydroxy acid.

- 5 The alpha hydroxy acid is suitably present in an amount of from 0.001% to 70%, preferably from 0.1% to 20%, most preferably from 1% to 10% by weight of the composition.

- 10 The keto acids can be chosen from  $\alpha$ -keto acids,  $\beta$ -keto acids and mixtures thereof. A particularly preferred  $\alpha$ -keto acid is 2-keto octanoic acid.

- 15 Preferably the amount of the organic acid component where present in the composition according to the invention is from 0.01 to 20%, more preferably from 0.05 to 10% and most preferably from 0.1 to 2% by weight.

- 20 Sterols may conveniently be selected from cholesterol, pro-vitamin D<sub>3</sub>, campesterol, stigmasterol, stigmasterol, 5-dihydrocholesterol,  $\alpha$ -spinasterol, palysterol, clionasterol,  $\gamma$ -sitosterol, stigmastenol, sargasterol, avenasterol, ergostanol, sitosterol, corbisterol, chondrillasterol, poriferasterol, haliclonaseterol, neospongosterol, fucosterol, aptostanol, Ergostadienol, ergosterol, 22-dihydroergosterol, brassicasterol, 24-methylenecholesterol, 5-dihydroergosterol, dehydroergosterol, 14-dehydroergosterol, 24-dehydroergosterol, fungisterol, cholestanol, coprostanol, Zymosterol, 7-hetocholesterol, Lathosterol, 22-dehydrocholesterol; 6-sitosterol, cholestatrien-3 $\beta$ -01, 25 coprostanol, cholestanol, ergosterol, 7-dehydrocholesterol, 24-dehydrocholest-adione-3 $\beta$ -01, equilenin, equilin, estrone, 17 $\beta$ -estradiol, Androst-4-ene-3 $\beta$ , 17 $\beta$ -diol, 30 dehydroepiandrosterone and mixtures thereof. Cholesterol is preferred.
- 35

- 17 -

The fatty acids are preferably essential fatty acids chosen from linoleic acid,  $\gamma$ -linolenic acid, homo- $\gamma$ -linolenic acid, columbinic acid, eicosa-(n-6,9,13)-trienoic acid, arachidonic acid,  $\alpha$ -linolenic acid, timnodonic acid, 5 hexaenoic acid and mixtures thereof.

Non-essential fatty acids can also be employed in addition to or in place of essential fatty acids, examples of which are chosen from myristic, palmitic, stearic and isostearic 10 acids, and mixtures thereof.

Compositions according to the invention may also include chelating agents, particularly those having high affinity with zinc and/or magnesium ions. 15

Suitable chelating agents may conveniently be selected from aminocarboxylic acids or salts thereof, polyphosphoric acids or salts thereof, diphosphonic acids, salts of diphosphonic acids, tertiary amines, aminophosphonic acids, 20 iminodiacetic acid derivatives, azines, hydroxyquinolines, and amino acid esters.

Examples of suitable chelating agents include but are not limited to ethylene diamine tetraacetic acid, a salt of 25 ethylene diamine tetraacetic acid, sodium pyrophosphate, sodium tripolyphosphate, 8-hydroxyquinoline, DL-(Methylene)dinitrolo tetra acetic acids, trans-decahydronaphthylene-trans-2, 3-bis-iminodiacetic, aminophenyl methylene diphosphonic acid, ethylene-bis-N,N1-(2,6-carboxyl) piperdine, adenosine triphosphate, L- 30 cysteine methyl ester and 8-hydroxyquinoline.

Preferred chelating agents are EDTA and/or pyrophosphate, and/or 8-hydroxy quinoline due to their ready availability, 35 excellent performance, relatively low cost, and safety in use.

- 18 -

The chelating agent is employed in the inventive compositions in an amount effective to enhance the activity of the enzyme. It will be appreciated that the precise amount will depend on the particular chelating agent used.  
5 Typically, the amount is in the range of 0.1 to 2%, preferably from 0.2 to 2% by weight of the composition.

Compositions according to the invention are useful in treating or alleviating conditions of the skin which are  
10 characterised by hyperkeratinisation, decreased rate of desquamation or abnormal desmosomal formation.

Accordingly, the invention provides the cosmetic or pharmaceutical use of a composition comprising one or more  
15 stratum corneum trypsin-like enzymes, particularly in the treatment of conditions where the underlying aetiology indicates that assisting desquamation and/or desmosomal degradation would be beneficial.

20 The invention further provides a method of treating skin comprising topically administering thereto a composition comprising one or more stratum corneum trypsin-like enzymes.

25 It will be appreciated that compositions according to the invention will primarily be of use in the treatment of established symptoms although prophylaxis is not excluded.

Compositions according to the invention are of use in  
30 treating or preventing diseases of the skin such as psoriasis, ichthyosis and acne. Compositions according to the invention are of particular interest in treating dry and/or flaky skin and in smoothing and enhancing the quality of skin. The compositions may also be used to  
35 alleviate dandruff.

It will be appreciated that the amount of the composition

- 19 -

and the frequency of its application to the skin will depend on the condition of the patient.

- 5 In use, a small quantity of the composition, for example from 1 to 5ml, is applied to areas of the skin or scalp, from a suitable container or applicator and, if necessary, it is then spread over and/or rubbed into the skin or scalp using the hand or fingers or a suitable device.
- 10 The topical skin treatment compositions according to the invention may be formulated in conventional manner using one or more cosmetically and/or pharmaceutically acceptable carriers or excipients.
- 15 For example, the topical compositions of the invention may suitably be formulated as a lotion having a viscosity of from 4,000 to 10,000 mPas, a fluid cream having a viscosity of from 10,000 to 20,000 mPas or a cream having a viscosity of from 20,000 to 100,000 mPas, or above. The composition can be packaged in a suitable container to suit its viscosity and intended use by the consumer. For example, a lotion or fluid cream can be packaged in a bottle or a roll-ball applicator or a propellant-driven aerosol device or a container fitted with a pump suitable for finger operation. When the composition is a cream, it can simply be stored in a non-deformable bottle or squeeze container, such as a tube or a lidded jar. The composition may be used for general lotions and creams, leave-on-creams, wash-off cleansers, face masks shampoos and bath oils.
- 20  
25  
30

The invention accordingly also provides a closed container containing an acceptable composition as herein defined.

35

- 20 -

## CHARACTERISATION OF STRATUM CORNEUM TRYPSIN-LIKE ENZYMES.

## 1) Superose 12 fractionation

5 Stratum corneum trypsin-like activity was derived from  
either human tape stripped or freeze scraped pig stratum  
corneum. The tissues were extracted in 1M sodium chloride  
in 0.05M sodium acetate pH6, 0.1% (v/v) Triton X-100 at 4°C  
10 and the extracts were fractionated using a Superose 12 gel  
filtration column (Pharmacia) with a buffer of 0.02M sodium  
acetate pH6 containing 1M sodium chloride.

The column was calibrated using standard proteins, namely  
haemoglobin (68KDa), carbonic anhydrase (29KDa), bovine  
15 chymotrypsin (25KDa) and cytochrome c (14KDa). The void  
volume was determined using dextran blue and the bed volume  
using CuSO<sub>4</sub>. Stratum corneum trypsin-like enzyme detected  
by boc-phe-ser-arg-AMC hydrolysis had an apparent molecular  
weight of 29 KDa on this system (Figure 1).

20

## 2) Cation exchange chromatography

Further purification was achieved using cation exchange  
chromatography with a Mono S column (Pharmacia). The 29kDa  
25 fraction from the Superose 12 column was desalted, loaded  
onto the Mono S column in 0.02M ammonium acetate pH5 and  
eluted with a gradient of 1M sodium chloride over 30  
fractions (Figure 2) and was started at fraction 11.

30 Activity was determined using the fluorescent proteolytic  
substrate boc-phe-ser-arg-amido-methylcoumarin by  
incubating in 50mM tris-HCl pH7.5, 0.1% (v/v) Triton X100,  
0.1% (w/v) sodium azide containing 100µM boc-phe-ser-arg-  
amido-methylcoumarin and incubated at 37°C for 3h.  
35 Termination of the reaction was by addition of 250µl of  
100mM sodium monochloroacetic acid, 30mM sodium acetate,  
70mM acetic acid, pH4.3 and proteolytic activity was

- 21 -

determined using a Perkin Elmer LS50 fluorescence spectrophotometer with emission at 380nm and detection at 460nm.

5 Caseinolysis was determined using casein zymography by a modification of Horie et al, "Detection and characterisation of epidermal proteinases by polyacrylamide gel electrophoresis", Comp. Biochem. Physiol 77B, 349-353 (1984). The samples were fractionated by sodium dodecyl  
10 sulphate (SDS) polyacrylamide gel electrophoresis using 12% gels containing 0.2% (w/v) casein. After fractionation, the gels were washed to remove SDS and incubated in 0.1M tris pH8 for 24h. The reaction was stopped by staining with coomassie blue in 10% acetic acid and 40% methanol.  
15 Caseinolysis was determined from densitometric analysis of the clear band produced by the protease.

Only one fraction contained both boc-phe-ser-arg-AMC hydrolytic and caseinolytic activities, indicating stratum  
20 corneum trypsin-like activity.

### 3) Inhibition profile

An inhibition profile for the stratum corneum trypsin-like  
25 enzyme was produced using specific protease inhibitors. Boc-phe-ser-arg-AMC hydrolytic activity was determined and expressed as a percentage of the control value (Figure 3). The concentrations of inhibitors used were 2mM PMSF, 1 $\mu$ M aprotinin, 100 $\mu$ M leupeptin, 100 $\mu$ M antipain, 100 $\mu$ M  
30 chymostatin, 100 $\mu$ M zinc sulphate, 1 $\mu$ M pepstatin and 1 $\mu$ M E64.

Trypsin specificity was shown by the inhibition of boc-phe-ser-arg-AMC hydrolytic activity in the presence of the  
35 trypsin inhibitors leupeptin and antipain.

- 22 -

#### 4) Effect on desmosomal degradation

Human sunburn peeled stratum corneum was incubated with stratum corneum trypsin-like enzyme (boc-phe-ser-arg-AMC hydrolysis equivalent to 17 pmol AMC/h) for 20h in 0.1M tris pH8, 0.1% (w/v) sodium azide at 37°C.

After incubation, the skin was washed in tris buffered saline containing 0.5% (v/v) Tween 20 and incubated for 1h at 37°C with a desmosomal marker antibody ( $\alpha$ 48/46) raised against the 46 and 48 kDa N-terminal fragments of human desmocollin 1 (dsc 1) (Gift from Dr I King, N.I.M.R). This was followed by incubating for 1h with an anti-rabbit IgG conjugated to FITC and the resulting fluorescence was detected by microscopy with a U.V. light source. The fluorescence was quantified from photographic negatives using an Epson GT8000 scanner coupled with Phoreti image analysis software.

The results obtained are presented graphically in Figure 4. The levels of dsc1 are significantly decreased by stratum corneum trypsin-like enzyme, indicating desmosomal degradation. This degradation was inhibited by leupeptin (100 $\mu$ M), a trypsin specific inhibitor.

5) The gel filtration purified 29kDa peak of boc-phe-ser-arg-AMC hydrolytic activity contained the trypsin-like caseinolytic proteases with 24, 26 and 27kDa apparent molecular weights. Using casein zymography, the inhibitor profiles of these proteases were determined.

Trypsin specificity was shown by the inhibition of caseinolysis in the presence of 100 $\mu$ M antipain, leupeptin and TLCK.

35



- 23 -

		<u>%inhib</u>	<u>sd</u>	<u>n</u>
Apparent molecular weight 27 KDa				
5	PMSF	68.7	22.0	4
	Aprotinin	85.4	11.5	4
	Chymostatin	82.6	15.1	3
	Leupeptin	77.8	16.8	4
	Antipain	68.7	26.8	4
10	TPCK	70.0	25.9	3
	TLCK	70.8	7.6	3

Apparent molecular weight 26 KDa				
15	PMSF	61.0	24.3	3
	Aprotinin	97.1	2.5	4
	Chymostatin	70.02	20.3	3
	Leupeptin	75.6	19.5	4
	Antipain	70.7	20.4	4
20	TPCK	58.6	32.6	3
	TLCK	65.4	15.2	4

Apparent molecular weight 24 KDa				
25	PMSF	77.6	19.05	3
	Aprotinin	95.5	6.36	4
	Chymostatin	70.4	28.13	4
	Leupeptin	50.6	55.87	4
	Antipain	24.0	65.11	3
30	TPCK	73.5	15.50	4
	TLCK	53.6	12.31	4

sd = standard deviation

n = number of samples

35

In order that the invention may be well understood, the following examples are given by way of illustration only.

- 24 -

Examples

The following examples are to illustrate compositions for topical application embodying the present invention.

5

A Typical Oil-In-Water Cream

		<u>% w/w</u>
10	SCTE	1.0
	Glycosidases	0.5
	Mineral oil	4.0
	Cetyl alcohol POE	4.0
	Cetyl alcohol	4.0
15	Triethanolamine	0.75
	Butane 1, 3 diol	3.0
	Xanthum gum	0.3
	Preservative	0.4
	Perfume	qs
20	Butylated hydroxytoluene	0.01
	Water	to 100

A Typical Lotion

25

		<u>% w/w</u>
	SCTE	1.0
	Ethanol	10.0
	Perfume	qs
30	Butylated hydroxytoluene	0.01
	Water	to 100

- 25 -

CLAIMS

- 5 1. A topical composition comprising one or more stratum corneum trypsin-like enzymes.
- 10 2. A composition according to claim 1 wherein the stratum corneum trypsin-like enzyme has an apparent molecular weight of 24, 26 or 27 KDa when determined by sodium dodecyl sulphate polyacrylamide gel electrophoresis as herein described.
- 15 3. A composition according to claim 1 or 2 wherein the stratum corneum trypsin-like enzyme is present in an amount of from 0.00001 to 50% by weight of the composition.
- 20 4. A composition according to any one of claims 1 to 3 wherein the stratum corneum trypsin-like enzyme is present in an amount of from 0.001 to 20% by weight of the composition.
- 25 5. A composition according to any one of claims 1 to 4 wherein the composition additionally comprises an enzyme selected from glycosidases, other proteases, ceramidases, lipases and mixtures thereof.
- 30 6. A composition according to claim 5 wherein the additional enzyme is present in an amount of from 0.00001 to 50% by weight of the composition.
- 35 7. A composition according to any one of claims 1 to 6 further comprising one or more ingredients selected from sunscreens, hydroxycarboxylic acids, ketocarboxylic acids, ceramides, pseudoceramides, polyol fatty acid polyesters, sterols, phospholipids, galactosyldiacylglycerols, glycosphingolipids, fatty acids or esters thereof.

- 26 -


8. The use of a composition according to any one of claims 1 to 7 for topical application to dry skin conditions, acne and dandruff and/or for smoothing skin.

- 5 9. A method of relieving or ameliorating dry skin conditions, acne and dandruff and/or for smoothing skin which includes the topical application to the skin of a composition comprising one or more stratum corneum trypsin-like enzymes.

10

Fig.1.


Stratum corneum trypsin-like enzyme: Superose 12 fractionation



2 / 4

Fig.2.


Cation exchange chromatography of 29kDa boc-phe-ser-arg-AMC hydrolytic activity




3 / 4

Fig.3.

Stratum corneum 29kDa trypsin-like enzyme" inhibition profile







## INTERNATIONAL SEARCH REPORT

Intern al Application No

PCT/EP 94/03001

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 6 A61K7/48 A61K38/48

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO,A,93 19732 (HENKEL KGAA) 14 October 1993 see the whole document ---	1,3-6,8, 9
P,X	WO,A,93 19731 (UNILEVER PLC.) 14 October 1993 see the whole document ---	1,3-6,8, 9
A	ACTA DERMATO-VENEREOLOGICA, vol.71, no.6, 1991, STOCKHOLM SE pages 471 - 474 LUNDSTRÖM ET AL. 'stratum corneum chymotryptic enzyme' cited in the application ---	1,2
A	LU,A,61 123 (BLENDAX-WERKE) 12 June 1970 see the whole document ---	1-9
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \* "A" document defining the general state of the art which is not considered to be of particular relevance
- \* "E" earlier document but published on or after the international filing date
- \* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \* "O" document referring to an oral disclosure, use, exhibition or other means
- \* "P" document published prior to the international filing date but later than the priority date claimed

- \* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* "&" document member of the same patent family

Date of the actual completion of the international search

4 January 1995

Date of mailing of the international search report

19.01.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax (+31-70) 340-3016

Authorized officer

Couckuyt, P

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 94/03001

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PATENT ABSTRACTS OF JAPAN vol. 17, no. 674 (C-1140) & JP,A,52 021 844 (KYOEI KAGAKU KOGYO KK) 31 August 1993 see abstract ---	1-9
A	DATABASE WPI Week 8325, Derwent Publications Ltd., London, GB; AN 83-59509K & JP,A,58 077 808 (KAKUDAI SHOSAN KK) 11 May 1983 see abstract ---	1-9
A	PATENT ABSTRACTS OF JAPAN vol. 8, no. 106 (C-223) & JP,A,59 020 211 (AYUKAWA TAIZOU) 1 February 1984 see abstract ---	1-9
A	EP,A,0 498 532 (SQUIBB & SONS INC.) 12 August 1992 see claims ---	1,8,9
P,A	DE,A,43 05 460 (SCHELLER A.) 25 August 1994 see the whole document -----	1,8,9

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 94/03001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9319732	14-10-93	AU-B- 3896293	08-11-93
WO-A-9319731	14-10-93	AU-B- 3896193	08-11-93
LU-A-61123	12-08-70	BE-A- 751739	16-11-70
		CH-A- 534518	15-03-73
		DE-A- 1930064	14-01-71
		FR-A, B 2046730	12-03-71
		GB-A- 1255284	01-12-71
		NL-A- 7008226	15-12-70
		BE-A- 754514	18-01-71
		CH-A- 537185	13-07-73
		DE-A- 1940105	18-02-71
		FR-A- 2057030	07-05-71
EP-A-0498532	12-08-92	NONE	
DE-A-4305460	25-08-94	AU-B- 6373094	14-09-94
		WO-A- 9419005	01-09-94

**THIS PAGE BLANK (USPTO)**